BACKGROUND: Acute otitis media is one of the most commonly-diagnosed childhood infections. This study assessed the efficacy of a novel vaccine that contained polysaccharides from 11 different Streptococcus pneumoniae serotypes each conjugated to Haemophilus influenzae-derived protein D in prevention of acute otitis media. METHODS: 4968 infants were randomly assigned to receive either pneumococcal protein D conjugate or hepatitis A vaccine at the ages of 3, 4, 5, and 12-15 months and were followed-up until the end of the second year of life. Middle-ear fluid was obtained for bacteriological culture and serotyping in children who presented with abnormal tympanic membrane or presence of middle-ear effusion, plus two predefined clinical symptoms. The primary endpoint was protective efficacy against the first episode of acute otitis media caused by vaccine pneumococcal serotypes. Analysis was per protocol. FINDINGS: From 2 weeks after the third dose to 24-27 months of age, 333 clinical episodes of acute otitis media were recorded in the protein D conjugate group (n=2455) and 499 in the control group (n=2452), giving a significant (33.6% [95% CI 20.8-44.3]) reduction in the overall incidence of acute otitis media. Vaccine efficacy was shown for episodes of acute otitis media caused by pneumococcal vaccine serotypes (52.6% [35.0-65.5] for the first episode and 57.6% [41.4-69.3] for any episode). Efficacy was also shown against episodes of acute otitis media caused by non-typable H influenzae (35.3% [1.8-57.4]). The vaccine reduced frequency of infection from vaccine-related cross-reactive pneumococcal serotypes by 65.5%, but did not significantly change the number of episodes caused by other non-vaccine serotypes. INTERPRETATION: These results confirm that using the H influenzae-derived protein D as a carrier protein for pneumococcal polysaccharides not only allowed protection against pneumococcal otitis, but also against acute otitis media due to non-typable H influenzae. Whether this approach would also allow improved protection against lower respiratory tract infections warrants further investigation.

Department of Epidemiology Faculty of Military Health Sciences University of Defence Hradec Kralove Czech Republic

000      

00000naa 2200000 a 4500

001      

bmc07520460

003      

CZ-PrNML

005      

20111210131131.0

008      

090402s2006 xxk e eng||

009      

AR

040    __

$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxk

100    1_

$a Prymula, Roman, $d 1964- $7 nlk19990073741

245    10

$a Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study / $c Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, Kohl I, Lommel P, Poolman J, Prieels JP, Schuerman L.

314    __

$a Department of Epidemiology, Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic. prymula@pmfhk.cz

520    9_

$a BACKGROUND: Acute otitis media is one of the most commonly-diagnosed childhood infections. This study assessed the efficacy of a novel vaccine that contained polysaccharides from 11 different Streptococcus pneumoniae serotypes each conjugated to Haemophilus influenzae-derived protein D in prevention of acute otitis media. METHODS: 4968 infants were randomly assigned to receive either pneumococcal protein D conjugate or hepatitis A vaccine at the ages of 3, 4, 5, and 12-15 months and were followed-up until the end of the second year of life. Middle-ear fluid was obtained for bacteriological culture and serotyping in children who presented with abnormal tympanic membrane or presence of middle-ear effusion, plus two predefined clinical symptoms. The primary endpoint was protective efficacy against the first episode of acute otitis media caused by vaccine pneumococcal serotypes. Analysis was per protocol. FINDINGS: From 2 weeks after the third dose to 24-27 months of age, 333 clinical episodes of acute otitis media were recorded in the protein D conjugate group (n=2455) and 499 in the control group (n=2452), giving a significant (33.6% [95% CI 20.8-44.3]) reduction in the overall incidence of acute otitis media. Vaccine efficacy was shown for episodes of acute otitis media caused by pneumococcal vaccine serotypes (52.6% [35.0-65.5] for the first episode and 57.6% [41.4-69.3] for any episode). Efficacy was also shown against episodes of acute otitis media caused by non-typable H influenzae (35.3% [1.8-57.4]). The vaccine reduced frequency of infection from vaccine-related cross-reactive pneumococcal serotypes by 65.5%, but did not significantly change the number of episodes caused by other non-vaccine serotypes. INTERPRETATION: These results confirm that using the H influenzae-derived protein D as a carrier protein for pneumococcal polysaccharides not only allowed protection against pneumococcal otitis, but also against acute otitis media due to non-typable H influenzae. Whether this approach would also allow improved protection against lower respiratory tract infections warrants further investigation.

650    _2

$a akutní nemoc $7 D000208

650    _2

$a bakteriální proteiny $x imunologie $7 D001426

650    _2

$a transportní proteiny $x imunologie $7 D002352

650    _2

$a dvojitá slepá metoda $7 D004311

650    _2

$a Haemophilus influenzae $x izolace a purifikace $x klasifikace $x patogenita $7 D006193

650    _2

$a vakcína proti hepatitidě A $7 D022362

650    _2

$a imunoglobulin D $7 D007072

650    _2

$a lidé $7 D006801

650    _2

$a kojenec $7 D007223

650    _2

$a lipoproteiny $x imunologie $7 D008074

650    _2

$a otitis media $x imunologie $x mikrobiologie $x prevence a kontrola $7 D010033

650    _2

$a otitis media s výpotkem $x mikrobiologie $7 D010034

650    _2

$a pneumokokové vakcíny $x imunologie $x terapeutické užití $7 D022242

650    _2

$a bakteriální polysacharidy $x imunologie $7 D011135

650    _2

$a sérotypizace $7 D012703

650    _2

$a Streptococcus pneumoniae $x izolace a purifikace $x klasifikace $x patogenita $7 D013296

650    _2

$a financování organizované $7 D005381

655    _2

$a randomizované kontrolované studie $7 D016449

700    1_

$a Peeters, Pascal

700    1_

$a Chrobok, Viktor, $d 1964- $7 mzk2003169418

700    1_

$a Křížová, Pavla $7 xx0048673

700    1_

$a Nováková, Elena, $d 1960- $7 xx0079047

700    1_

$a Kalíšková, Eva $7 xx0127841

700    1_

$a Kohl, Igor

700    1_

$a Lommel, Patricia

700    1_

$a Poolman, Jan

700    1_

$a Prieels, Jean-Paul

700    1_

$a Schuerman, Lode

773    0_

$w MED00010161 $t The lancet $g Roč. 367, č. 9512 (2006), s. 740-748 $x 0140-6736

910    __

$a ABA008 $b x $y 9

990    __

$a 20090325104238 $b ABA008

991    __

$a 20090713161003 $b ABA008

999    __

$a ok $b bmc $g 638263 $s 491062

BAS    __

$a 3

BMC    __

$a 2006 $b 367 $c 9512 $d 740-748 $i 0140-6736 $m Lancet $x MED00010161

LZP    __

$a 2009-B1/dkme